Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma

Malignant melanoma is associated with poor clinical prognosis; however, novel molecular and immune therapies are now improving patient outcomes. Almost 50% of melanomas harbor targetable activating mutations of BRAF which promote RAS-RAF-MEK-ERK pathway activation and melanoma proliferation. Recent...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cancer Ther
Egile Nagusiak: Ilieva, Kristina M., Correa, Isabel, Josephs, Debra H., Karagiannis, Panagiotis, Egbuniwe, Isioma U., Cafferkey, Michiala J., Spicer, James F., Harries, Mark, Nestle, Frank O., Lacy, Katie E., Karagiannis, Sophia N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4258403/
https://ncbi.nlm.nih.gov/pubmed/25385327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0290
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak